ASCO 2023 – Warner Biddle
While ASCO 2023 didn’t have too much focus on cell therapies, because of their lack of impact so far on the solid tumour space, Kite, a Gilead company, did share new data on Yescarta for large B-cell lymphoma.
Warner Biddle, SVP and head of commercial at Kite, spoke with Jonah Comstock, pharmaphorum's editor-in-chief, about the ZUMA-7 trial and its strong showing in overall survival for patients who haven’t seen a major practice shift in more than 30 years.
They also talked about some of the other work Kite is doing in this space, including new data in the acute lymphoblastic leukaemia space, where they demonstrated a more than two-year median overall survival.
Tune in for a wide-ranging conversation about cell therapy and how it's growing as a business area at Kite and beyond.
